---
figid: PMC5611863__nihms897656f1
figtitle: Landscape of new drugs in lymphoma
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC5611863
filename: nihms897656f1.jpg
figlink: /pmc/articles/PMC5611863/figure/F1/
number: F1
caption: 'a | BCR signalling pathway. Selective inhibitors for Syk and Btk are either
  approved by regulatory agencies or are in clinical trials. b | SYK structure. SYK
  is a non-receptor protein-tyrosine kinase containing tandem SRC homology 2 (SH2)
  domains. SYK inhibitors are able to competitively bind to the ATP-binding pocket
  of the kinase domain. Most BTK inhibitors bind covalently to cysteine 481 (C481)
  residues in the BTK active site, c | BTK structure. BTK is composed of four major
  domains: an N-terminal pleckstrin homology (PH) domain, a TEC homology (TH) domain,
  two SRC homology domains (SH3 followed by SH2), and a C-terminal kinase domain.
  d | A list of kinases that contain a C481 residue in the active kinase site. The
  IC50 is shown for ibrutinib using a purified kinase assay.'
papertitle: The landscape of new drugs in lymphoma.
reftext: Anas Younes, et al. Nat Rev Clin Oncol. ;14(6):335-346.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9640981
figid_alias: PMC5611863__F1
figtype: Figure
redirect_from: /figures/PMC5611863__F1
ndex: be3a65d8-deb0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5611863__nihms897656f1.html
  '@type': Dataset
  description: 'a | BCR signalling pathway. Selective inhibitors for Syk and Btk are
    either approved by regulatory agencies or are in clinical trials. b | SYK structure.
    SYK is a non-receptor protein-tyrosine kinase containing tandem SRC homology 2
    (SH2) domains. SYK inhibitors are able to competitively bind to the ATP-binding
    pocket of the kinase domain. Most BTK inhibitors bind covalently to cysteine 481
    (C481) residues in the BTK active site, c | BTK structure. BTK is composed of
    four major domains: an N-terminal pleckstrin homology (PH) domain, a TEC homology
    (TH) domain, two SRC homology domains (SH3 followed by SH2), and a C-terminal
    kinase domain. d | A list of kinases that contain a C481 residue in the active
    kinase site. The IC50 is shown for ibrutinib using a purified kinase assay.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCR
  - RN7SL263P
  - SYK
  - BTK
  - CD79A
  - CD79B
  - CD19
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - LYN
  - CDK5RAP2
  - BLNK
  - PLCG1
  - PLCG2
  - NM
  - PRKCB
  - CARD11
  - NFKB1
  - TEC
  - EPHB2
  - MAPK1
  - MAPK3
  - ITK
  - BMX
  - TXK
  - EGFR
  - FOS
  - FOSB
  - FOSL1
  - FOSL2
  - JUN
  - JUNB
  - JUND
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - ERBB2
  - ERBB4
  - BLK
  - BIK
  - JAK3
  - Ibrutinib
  - Cancer
---
